DNER and cancer: This discovery generated interest in utilizing BET proteins for cancer therapy.14–19 In a 2008 patent (PCT/JP2008/073864), BET inhibitors were initially described as agents that exhibit antitumor activity by diminishing the interaction between BD-containing proteins and acetylated histones.